Teva Q1 2026: $700M Emalex acquisition announced; AUSTEDO growth offsets lenalidomide decline
Filed April 29, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 7, 2025 · ~2 min read
5 material changes detected in this filing.
Create a free account to read the full summary — it takes 30 seconds.
Partner
Trade TEVJF commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 2, 2026 8:24 PM